Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion
Αποθηκεύτηκε σε:
David, S.P., ET AL., Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction, Vol. 108, no. 12 (2013), p. 2202-2211.
Ref.
196574
Τοποθεσία:
SIIS R.696 Archivo
Palabras clave:
Drogodependencias, Efectos, Fármacos, Genética, Predicción, Resultados, Tabaquismo, Tratamiento médico
Drogodependencias, Efectos, Fármacos, Genética, Predicción, Resultados, Tabaquismo, Tratamiento médico
Παρόμοια τεκμήρια: Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion
- Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
- GENETIC VARIATION IN THE SEROTONIN PATHWAY AND SMOKING CESSATION WITH NICOTINE REPLACEMENT THERAPY: NEW DATA FROM THE PATCH IN PRACTICE TRIAL AND POOLED ANALYSES
- A RANDOMIZED TRIAL OF SHORT PSYCHOTHERAPY VERSUS SUSTAINED-RELEASE BUPROPION FOR SMOKING CESSATION
- Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta analysis of randomized controlled trials
- BUPROPION SR AND CONTINGENCY MANAGEMENT FOR ADOLESCENT SMOKING CESSATION
- CLINICAL EFFICACY OF CITALOPRAM ALONE OR AUGMENTED WITH BUPROPION IN METHADONE STABILIZED PATIENTS